The global biosimilars market is expected to reach USD 13.1 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. Rising demand for the cost-effective therapies is expected to drive the market in the forecast period. Biosimilars are about 30% cheaper ... Read more
Bharat Book Bureau Provides the Trending Market Research Report on "Global Biologics and Biosimilars Market Size study, by Type, by Applications, by and Regional Forecasts 2018-2025" under Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and industry reports.
In recent years, biosimilars have emerged as a groundbreaking development in the field of healthcare. These biologic drugs, often referred to as the "generic" version of complex biologic medicines, offer great promise in terms of cost-effectiveness, improved patient access, and enhanced treatment options. This blog aims to delve into the world of biosimilars, exploring their definition, regulatory framework, benefits, challenges, and their potential ... Read more
Biosimilars are biological medical products that are developed to be similar to an already licensed biological product, known as reference medicinal product (RPM). Biosimilars offer an effective alternate to expensive biopharmaceutical drugs with similar quality, safety, and efficacy. They seek to expand patient access to lifesaving medicines by reducing costs. For example, biosimilars have the potential to treat various chronic diseases like cancer, diabetes, and autoimmune conditions at a ... Read more
Introduction to Biosimilars
Biosimilars are biologic medical products that are developed to be similar to an already licensed biologic product, known as the reference biologic product (or reference product). Biosimilars undergo rigorous testing to ensure they are as safe and effective as the originator biologic product. Key factors driving the development of biosimilars include the expiry of patents covering reference biologics and the potential for more affordable treatment options. ... Read more
